363 related articles for article (PubMed ID: 17458947)
1. De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
Herschhorn A; Lerman L; Weitman M; Gleenberg IO; Nudelman A; Hizi A
J Med Chem; 2007 May; 50(10):2370-84. PubMed ID: 17458947
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
[TBL] [Abstract][Full Text] [Related]
5. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
[TBL] [Abstract][Full Text] [Related]
6. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
[TBL] [Abstract][Full Text] [Related]
8. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
He X; Mei Y; Xiang Y; Zhang DW; Zhang JZ
Proteins; 2005 Nov; 61(2):423-32. PubMed ID: 16114038
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
Borkow G; Fletcher RS; Barnard J; Arion D; Motakis D; Dmitrienko GI; Parniak MA
Biochemistry; 1997 Mar; 36(11):3179-85. PubMed ID: 9115994
[TBL] [Abstract][Full Text] [Related]
10. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Das K; Lewi PJ; Hughes SH; Arnold E
Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
[TBL] [Abstract][Full Text] [Related]
11. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamide.
Herschhorn A; Oz-Gleenberg I; Hizi A
Biochemistry; 2008 Jan; 47(1):490-502. PubMed ID: 18052256
[TBL] [Abstract][Full Text] [Related]
14. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
Herschhorn A; Hizi A
J Med Chem; 2008 Sep; 51(18):5702-13. PubMed ID: 18800765
[TBL] [Abstract][Full Text] [Related]
16. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.
Nugent RA; Schlachter ST; Murphy MJ; Cleek GJ; Poel TJ; Wishka DG; Graber DR; Yagi Y; Keiser BJ; Olmsted RA; Kopta LA; Swaney SM; Poppe SM; Morris J; Tarpley WG; Thomas RC
J Med Chem; 1998 Sep; 41(20):3793-803. PubMed ID: 9748354
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
Budihas SR; Gorshkova I; Gaidamakov S; Wamiru A; Bona MK; Parniak MA; Crouch RJ; McMahon JB; Beutler JA; Le Grice SF
Nucleic Acids Res; 2005; 33(4):1249-56. PubMed ID: 15741178
[TBL] [Abstract][Full Text] [Related]
19. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
20. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
